Physician profile
Solange Kwam
NPI 1033607999
$2,680.10
in general payments reported to CMS, 2019-2025
19 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $1,420 · 2023: $860 · 2024: $121 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.82 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $400.41 | 2021-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lilly USA, LLC | $287.87 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $250.53 | 2022-2024 | Wegovy |
| Alkermes, INC. | $214.79 | 2022 | |
| Abbvie INC. | $214.67 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $129.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $121.12 | 2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $120.58 | 2022 | |
| Idorsia Pharmaceuticals US INC | $103.22 | 2023 | Quviviq |
| Gilead Sciences, INC. | $102.65 | 2023 | |
| Abbott Laboratories | $92.13 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $69.69 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.34 | 2021 | |
| Glaxosmithkline, LLC. | $17.74 | 2023 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.53 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $16.15 | 2021 | |
| Averitas Pharma INC. | $14.25 | 2025 | Qutenza |
| Hikma Pharmaceuticals USA | $12.99 | 2023 | Ryaltris, Mitigare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solange Kwam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.